Resistance mechanisms to osimertinib in EGFR-mutated non-small cell lung cancer

Osimertinib is an irreversible, third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor that is highly selective for EGFR-activating mutations as well as the EGFR T790M mutation in patients with advanced non-small cell lung cancer (NSCLC) with EGFR oncogene addiction. Desp...

Descripción completa

Detalles Bibliográficos
Autores principales: Leonetti, Alessandro, Sharma, Sugandhi, Minari, Roberta, Perego, Paola, Giovannetti, Elisa, Tiseo, Marcello
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2019
Materias:
Review Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6889286/
https://www.ncbi.nlm.nih.gov/pubmed/31564718
http://dx.doi.org/10.1038/s41416-019-0573-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6889286/
https://www.ncbi.nlm.nih.gov/pubmed/31564718
http://dx.doi.org/10.1038/s41416-019-0573-8

Ejemplares similares